Radius Health (RDUS) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Radius Health, Inc. First Quarter 2022 Results
May 5, 2022 7:30 AM EDTQ1 2022 TYMLOS® product net revenue of $43 million vs. $45 million in Q1 2021
° Q1 results: in-line with previously guided 1H 2022 company target of $97 million
° Reiterating FY 2022 TYMLOS Net Revenue guidance of $232 million
° Seasonality, as previously announced: 42% of net revenue in 1H and 58% in 2H 2022
° Patient Growth: average active patients on therapy increased by 4% compared to Q1 2021Productivity improvement continued: revenue per commercial headcount up 32% vs. Q1 2021TYMLOS for the Male indication: sNDA filed in Q1 2022 with launch planned for early Q1 2023Additional patent granted by USPTO for TYMLOS: extending exclusivity to January 10,... More
